Discover
MTSR
Metsera, Inc.
70.50
2 x 50.92
2 x 90.56
bid
ask
+
0.00
0.00%
04:00 PM
timesize
| Ytd | 0.00% | |
| 1y | 0.00% |
70.13
day range
70.76
12.30
52 week range
83.86
| Open | 70.74 | Prev Close | 70.50 | Low | 70.13 | High | 70.76 | Mkt Cap | 7.43B |
| Vol | 27.87M | Avg Vol | 3.50M | EPS | -2.99 | P/E | -23.58 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | 2.52 | Inst. Own | 90.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-25 | 50-d Avg | 53.47 | 200-d Avg | 35.09 | 1yr Est | 57.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-03-25 | 2025-12 | -0.54 | N/A | N/A | N/A |
| 2025-11-12 | 2025-09 | -0.56 | -1.11 | -0.55 | -98.21% |
| 2025-07-28 | 2025-06 | -0.66 | -0.66 | N/A | -0.29% |
| 2025-05-12 | 2025-03 | -0.85 | -1.03 | -0.18 | -21.18% |
| 2025-03-26 | 2024-12 | -0.8 | -3.52 | -2.72 | -340.00% |
| 2025-02-26 | 2024-10 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-09-24 | Leerink Partners | Downgrade | Outperform | Market Perform |
| 2025-09-09 | Leerink Partners | Upgrade | Outperform | |
| 2025-09-03 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2025-08-28 | B of A Securities | Upgrade | Buy | Buy |
| 2025-06-20 | Wells Fargo | Upgrade | Overweight | |
| 2025-06-10 | Guggenheim | Upgrade | Buy | Buy |
Profile
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-02-02 | ARCH VENTURE PARTNERS XII, LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2025-02-02 | BERNS PAUL L | Director | 0.00 | Purchase |
| 2025-02-02 | BUROW KRISTINA M | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2025-11-09 | FMR LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Gift |
| 2025-01-29 | WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN II | Beneficial Owner of more than 10% of a Class of Security | 1.86M | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-09-29 | FMR, LLC | 13.89M | 979.39M | 13.18% |
| 2025-09-29 | Vanguard Group Inc | 5.82M | 410.66M | 5.53% |
| 2025-09-29 | Janus Henderson Group PLC | 5.35M | 377.37M | 5.08% |
| 2025-09-29 | Blackrock Inc. | 3.84M | 270.39M | 3.64% |
| 2025-09-29 | Alphabet Inc. | 3.78M | 266.74M | 3.59% |
| 2025-09-29 | VR Adviser, LLC | 3.75M | 264.42M | 3.56% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-09-29 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.63M | 255.90M | 3.44% |
| 2025-07-30 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.11M | 148.50M | 2.00% |
| 2025-09-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.00M | 140.90M | 1.90% |
| 2025-09-29 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.50M | 105.41M | 1.42% |
| 2025-09-29 | SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF | 1.34M | 94.21M | 1.27% |
| 2025-09-29 | iShares Trust-iShares Russell 2000 ETF | 1.32M | 93.34M | 1.26% |